12 Yue 3 days, a study “The Lancet” published online, for CD30 -positive outer peripheral T -cell lymphoma patients, this rituximab, cyclophosphamide, doxorubicin and prednisone ( A + CHP ) Better than cyclophosphamide, doxorubicin, vincristine and prednisone ( CHOP ).
Steven Horwitz , MD, from the Memorial Sloan Kettering Cancer Center in New York City and colleagues conducted a double-blind, placebo-controlled, active-control phase 3 study involving 452 patients from 132 locations in 17 countries . These patients CD30- positive peripheral T- cell lymphoma without prior treatment . Patients with 1 : 1 random allocation ratio, accepts A + CHP or of CHOP , sustained 6 , or . 8 th 21 is day cycle.
The researchers found that the median progression-free survival ( PFS ) of the A + CHP group and the CHOP group were 48.2 and 20.8 months, respectively. The incidence of side effects was similar between the two groups, including febrile neutropenia ( 18 % and 15 %, respectively) and peripheral neuropathy ( 52 % and 55 %, respectively). Fatal adverse events occurred in 3 % and 4 % of patients, respectively.
In the CHP to add this cetuximab can improve progression-free and overall survival without increasing toxicity, the study supports the A + CHP for many CD30 positive outer peripheral T new standard treatment for lymphoma patients.